We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+12.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$70.9M
(+20%)
Cap. Flow
+$79.1M
Cap. Flow
% of AUM
18.34%
Top 10 Holdings %
Top 10 Hldgs %
23.13%
Holding
178
New
54
Increased
29
Reduced
23
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xtant Medical Holdings
XTNT
|
+$14.7M |
| 2 |
Palisade Bio
PALI
|
+$11M |
| 3 |
POL.WS
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
|
+$10.1M |
| 4 |
electroCore
ECOR
|
+$8.6M |
| 5 |
KLR
Kaleyra, Inc.
KLR
|
+$8.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$8.32M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$5.67M |
| 3 |
Sutro Biopharma
STRO
|
+$5.16M |
| 4 |
MBTCU
Nocturne Acquisition Corporation Unit
MBTCU
|
+$5M |
| 5 |
Imunon
IMNN
|
+$4.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.75% |
| 2 | Financials | 3.74% |
| 3 | Technology | 1.96% |
| 4 | Consumer Discretionary | 0.54% |
| 5 | Industrials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LITS
26
Lite Strategy Inc
LITS
$33.4M
| $5.21M | 1.21% |
91,403
+59,499
| +186% | +$3.82M |
|
27
Castle Biosciences
CSTL
$928M
| $5.06M | 1.17% |
69,000
+41,635
| +152% | +$2.75M |
|
|
MBTC
28
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $4.93M | 1.14% |
+500,000
| New | +$4.92M |
|
|
SIEN
29
DELISTED
Sientra, Inc.
SIEN
| $4.82M | 1.12% |
60,569
-13,336
| -18% | -$947K |
|
30
Cerus
CERS
$433M
| $4.81M | 1.12% |
+814,328
| New | +$4.77M |
|
31
Insulet
PODD
$11.8B
| $4.67M | 1.08% |
17,000
-4,000
| -19% | -$1.09M |
|
|
RNAM
32
DELISTED
Avidity Biosciences
RNAM
| $4.66M | 1.08% |
188,600
+10,000
| +6% | +$233K |
|
|
NVRO
33
DELISTED
NEVRO CORP.
NVRO
| $4.46M | 1.03% |
26,900
-11,000
| -29% | -$1.72M |
|
|
BCTX
34
Briacell Therapeutics
BCTX
$29.2M
| $4.27M | 0.99% |
+5,335
| New | +$3.33M |
|
35
Aurinia Pharmaceuticals
AUPH
$1.87B
| $4.26M | 0.99% |
328,908
-80,000
| -20% | -$1.02M |
|
36
Spyre Therapeutics
SYRE
$8.24B
| $4.24M | 0.98% |
24,388
+13,678
| +128% | +$2.49M |
|
37
Immatics
IMTX
$1.23B
| $4M | 0.93% |
344,558
| – | – |
|
38
Inspire Medical Systems
INSP
$1.5B
| $3.99M | 0.93% |
+20,655
| New | +$4.1M |
|
|
MREO
39
Mereo BioPharma
MREO
$50.4M
| $3.96M | 0.92% |
1,250,000
| – | – |
|
|
EUCR
40
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $3.94M | 0.91% |
+400,000
| New | +$3.94M |
|
41
Varex Imaging
VREX
$502M
| $3.79M | 0.88% |
141,319
+35,592
| +34% | +$873K |
|
42
Illumina
ILMN
$30B
| $3.79M | 0.88% |
8,224
| – | – |
|
43
Natera
NTRA
$38.7B
| $3.77M | 0.88% |
+33,230
| New | +$3.4M |
|
44
Ocular Therapeutix
OCUL
$1.84B
| $3.63M | 0.84% |
256,152
-70,022
| -21% | -$1.06M |
|
45
Immunovant
IMVT
$7.91B
| $3.54M | 0.82% |
335,041
+105,419
| +46% | +$1.47M |
|
|
IGMS
46
DELISTED
IGM Biosciences
IGMS
| $3.53M | 0.82% |
+42,473
| New | +$3.15M |
|
47
Haemonetics
HAE
$3.94B
| $3.53M | 0.82% |
53,000
+35,956
| +211% | +$2.54M |
|
|
NSTG
48
DELISTED
NanoString Technologies, Inc.
NSTG
| $3.53M | 0.82% |
+54,500
| New | +$3.46M |
|
49
Dyne Therapeutics
DYN
$4.71B
| $3.51M | 0.81% |
166,636
| – | – |
|
50
Celcuity
CELC
$4.28B
| $3.48M | 0.81% |
+145,000
| New | +$3.73M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Altium Capital Management held 178 positions worth $431M, up 20% from $360M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Altium Capital Management deployed $79.1M of net new capital in Q2 2021, opening 54 new positions and adding to 29 existing holdings. Its largest new stake was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Verastem, an estimated $2.98M trimmed.
- Altium Capital Management's largest Q2 2021 buy was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
- Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $7.41M increase.
- Altium Capital Management's biggest Q2 2021 reduction was Verastem, cutting an estimated $2.98M.
- Altium Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $8.32M.
- Altium Capital Management's ten largest holdings make up 23% of its $431M portfolio in Q2 2021.
- Altium Capital Management opened 54 new positions and closed 43 in Q2 2021.
- Altium Capital Management's portfolio value rose 20% quarter-over-quarter to $431M.
Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.